Physician
Chinatown True Care Medical PLLC
Chinatown True Care Medical PLLC was paid $94.78M by Medicaid between Feb 2020 and Dec 2024, across 446 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 34% of everything it billed.
33Billing provider infoCHINATOWN TRUE CARE MEDICAL PLLC
NEW YORK, NY 10013
NEW YORK, NY 10013
33aNPI1912567884assigned 06/13/2019
33bProvider typeFamily Medicine Physician
28Total paid$94.78M
24GClaims3,775,466
24DCodes billed446
24AFirst – last monthFeb 2020 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in New York
Rank by total paid#1 of 2,605
Median peer was paid$10K
This provider vs. median9,387×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 253,952 | $8.31M | |
| 2021 | 547,798 | $18.44M | |
| 2022 | 546,813 | $19.11M | |
| 2023 | 1,229,045 | $27.16M | |
| 2024incomplete | 1,197,858 | $21.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 415,763 | 364,011 | $32.01M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 176,545 | 159,826 | $18.58M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 6.2% | 13,995 | 13,986 | $5.85M |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 5.8% | 51,548 | 51,465 | $5.51M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 39,670 | 35,725 | $2.05M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.1% | 4,531 | 4,513 | $1.99M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.7% | 15,286 | 15,266 | $1.59M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.5% | 3,868 | 3,867 | $1.45M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.4% | 12,204 | 12,190 | $1.33M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.3% | 7,760 | 7,756 | $1.21M |
| 31231 | 1.2% | 6,194 | 5,796 | $1.16M | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.2% | 11,126 | 11,119 | $1.09M |
434 more codes
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.1% | 69,101 | $1000K |
| 99442 | 1.0% | 14,610 | $955K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 129,454 | $852K |
| 76641 | <1% | 6,382 | $754K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,327 | $689K |
| 93000 | <1% | 59,011 | $663K | |
| 90674 | <1% | 23,404 | $656K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 6,010 | $622K |
| 99051 | <1% | 146,361 | $618K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 4,080 | $585K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,670 | $521K |
| 99401 | <1% | 22,569 | $510K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 22,026 | $490K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 947 | $467K |
| 76536 | <1% | 4,353 | $412K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 4,243 | $383K |
| 96127 | <1% | 74,293 | $339K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 3,729 | $324K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,487 | $288K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,254 | $272K |
| 75574 | <1% | 1,060 | $260K | |
| 93229 | <1% | 407 | $246K | |
| 90756 | <1% | 9,436 | $244K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,661 | $240K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,240 | $235K |
| 99497 | <1% | 3,666 | $221K | |
| 92250 | <1% | 6,350 | $220K | |
| 99441 | <1% | 6,756 | $220K | |
| 88312 | <1% | 764 | $219K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,625 | $211K |
| 0064A | <1% | 5,250 | $205K | |
| 0012A | <1% | 5,110 | $191K | |
| 80061 | Lipid panel | <1% | 21,244 | $181K |
| 0011A | <1% | 5,806 | $178K | |
| 74183 | <1% | 559 | $171K | |
| 88313 | <1% | 763 | $162K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,540 | $159K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,763 | $152K |
| 36415 | Collection of venous blood by venipuncture | <1% | 178,350 | $146K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,403 | $138K |
| 19083 | <1% | 315 | $137K | |
| 90686 | <1% | 13,324 | $134K | |
| 80053 | Comprehensive metabolic panel | <1% | 17,685 | $116K |
| 3074F | <1% | 152,424 | $115K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,611 | $109K |
| 3078F | <1% | 141,113 | $106K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 3,398 | $101K |
| 92551 | <1% | 12,690 | $99K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,172 | $99K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,319 | $94K |
| 93880 | <1% | 654 | $92K | |
| 31575 | <1% | 694 | $87K | |
| 76830 | Ultrasound, transvaginal | <1% | 800 | $87K |
| 92060 | <1% | 1,370 | $86K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,015 | $83K |
| 71271 | <1% | 701 | $80K | |
| 10005 | <1% | 593 | $79K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 261 | $79K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 968 | $76K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 181 | $69K |
| 90651 | <1% | 1,357 | $69K | |
| 88173 | <1% | 392 | $66K | |
| 99443 | <1% | 738 | $63K | |
| 80050 | General health panel | <1% | 1,582 | $63K |
| 92083 | <1% | 1,038 | $61K | |
| 92552 | <1% | 2,404 | $61K | |
| 92015 | Determination of refractive state | <1% | 3,304 | $61K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 434 | $61K |
| 86480 | <1% | 1,556 | $60K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 342 | $55K |
| 71250 | <1% | 459 | $55K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,451 | $54K |
| 90715 | <1% | 1,794 | $54K | |
| 0002A | <1% | 1,354 | $53K | |
| 0001A | <1% | 1,398 | $52K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 927 | $52K |
| 90688 | <1% | 2,745 | $51K | |
| 84480 | <1% | 7,004 | $50K | |
| 84439 | <1% | 8,230 | $47K | |
| 93702 | <1% | 476 | $47K | |
| 0134A | <1% | 1,229 | $46K | |
| 69105 | <1% | 340 | $45K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 666 | $43K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 251 | $43K |
| 0124A | <1% | 1,036 | $40K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 3,567 | $39K |
| 93224 | <1% | 660 | $39K | |
| 0004A | <1% | 955 | $38K | |
| 90656 | <1% | 4,918 | $38K | |
| 99072 | <1% | 50,883 | $36K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 181 | $36K |
| 82607 | <1% | 3,641 | $35K | |
| 86328 | <1% | 1,168 | $34K | |
| 77080 | <1% | 1,110 | $34K | |
| 99406 | <1% | 3,139 | $33K | |
| 84153 | <1% | 2,848 | $32K | |
| 90461 | <1% | 2,398 | $32K | |
| 3079F | <1% | 38,895 | $32K | |
| 93351 | <1% | 169 | $32K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,251 | $31K |
| 82746 | <1% | 3,152 | $30K | |
| 88342 | <1% | 286 | $30K | |
| 99385 | <1% | 278 | $30K | |
| 77065 | Tomosynthesis, mammo | <1% | 253 | $28K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,279 | $28K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 622 | $28K |
| 72100 | <1% | 832 | $27K | |
| 84481 | <1% | 2,329 | $26K | |
| 86580 | <1% | 2,951 | $25K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,272 | $25K |
| 90750 | <1% | 777 | $25K | |
| 93978 | <1% | 172 | $25K | |
| 87517 | <1% | 924 | $24K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,260 | $24K |
| 93015 | <1% | 427 | $24K | |
| 99386 | <1% | 173 | $24K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,090 | $24K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,091 | $24K |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | <1% | 2,758 | $23K |
| H0001 | Alcohol and/or drug assessment | <1% | 2,583 | $23K |
| 82105 | <1% | 2,128 | $23K | |
| 88172 | <1% | 408 | $23K | |
| 76642 | <1% | 287 | $22K | |
| 96367 | <1% | 371 | $22K | |
| 93925 | <1% | 119 | $21K | |
| 0072A | <1% | 531 | $21K | |
| 82043 | <1% | 5,538 | $21K | |
| 84550 | <1% | 7,092 | $20K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,730 | $20K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 306 | $20K |
| 91320 | <1% | 263 | $20K | |
| 82728 | <1% | 2,173 | $19K | |
| 93979 | <1% | 228 | $19K | |
| 87340 | <1% | 2,856 | $19K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 242 | $18K |
| 90658 | <1% | 1,382 | $18K | |
| 82570 | <1% | 5,524 | $18K | |
| 76770 | <1% | 195 | $18K | |
| 81001 | <1% | 8,878 | $18K | |
| 88177 | <1% | 405 | $18K | |
| 97162 | <1% | 189 | $18K | |
| 3075F | <1% | 19,154 | $17K | |
| 73562 | <1% | 336 | $17K | |
| 0071A | <1% | 402 | $16K | |
| 92081 | <1% | 486 | $16K | |
| 97161 | <1% | 169 | $16K | |
| 91322 | <1% | 132 | $16K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,000 | $15K |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 404 | $15K |
| 69210 | <1% | 817 | $15K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 232 | $14K |
| 96160 | <1% | 10,227 | $14K | |
| 80076 | <1% | 2,727 | $14K | |
| 86803 | <1% | 1,574 | $13K | |
| 97014 | <1% | 932 | $13K | |
| 90661 | <1% | 1,480 | $13K | |
| 96415 | <1% | 390 | $13K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 250 | $13K |
| H0049 | Alcohol and/or drug screening | <1% | 1,899 | $12K |
| 92588 | <1% | 346 | $12K | |
| 90480 | <1% | 536 | $12K | |
| 0054A | <1% | 293 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 81 | $11K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 109 | $11K |
| 93241 | <1% | 47 | $11K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 219 | $11K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 38 | $11K |
| 90620 | <1% | 873 | $11K | |
| 92557 | <1% | 346 | $10K | |
| 92133 | <1% | 287 | $10K | |
| 72050 | <1% | 223 | $10K | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 53,118 | $9K |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 1,087 | $9K |
| 90673 | <1% | 216 | $9K | |
| 90682 | <1% | 141 | $9K | |
| 90837 | Psychotherapy session, about an hour | <1% | 74 | $9K |
| 74178 | <1% | 25 | $8K | |
| 99490 | Ccm add 20min | <1% | 488 | $8K |
| 96417 | <1% | 110 | $8K | |
| 90694 | <1% | 204 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 580 | $8K |
| 93970 | <1% | 53 | $8K | |
| 92570 | <1% | 301 | $8K | |
| 86706 | <1% | 1,713 | $7K | |
| 83880 | <1% | 320 | $7K | |
| 99459 | <1% | 338 | $7K | |
| 99173 | <1% | 9,923 | $7K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 26 | $7K |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 23 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 219 | $7K |
| 86787 | <1% | 842 | $7K | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | <1% | 217,451 | $7K |
| 81003 | <1% | 6,335 | $7K | |
| G8752 | Most recent systolic blood pressure < 140 mmhg | <1% | 208,919 | $7K |
| 93320 | <1% | 154 | $6K | |
| 93228 | <1% | 366 | $6K | |
| 3077F | <1% | 8,429 | $6K | |
| 84378 | <1% | 801 | $6K | |
| 83540 | <1% | 1,428 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 540 | $6K |
| 94010 | <1% | 404 | $6K | |
| 90746 | <1% | 80 | $5K | |
| 68761 | <1% | 29 | $5K | |
| 81025 | <1% | 754 | $5K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 306 | $5K |
| 76514 | <1% | 512 | $5K | |
| 86780 | <1% | 574 | $5K | |
| 83090 | <1% | 431 | $5K | |
| 99188 | <1% | 351 | $5K | |
| 92202 | <1% | 297 | $4K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 60 | $4K |
| 90619 | <1% | 586 | $4K | |
| 92625 | <1% | 90 | $4K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 70 | $4K |
| 86765 | <1% | 508 | $4K | |
| 84466 | <1% | 491 | $4K | |
| 86708 | <1% | 504 | $4K | |
| 86762 | <1% | 429 | $4K | |
| 73630 | <1% | 107 | $4K | |
| 82947 | <1% | 2,163 | $4K | |
| 99397 | <1% | 55 | $4K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 316 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 155 | $4K |
| 86735 | <1% | 421 | $3K | |
| 0154A | <1% | 87 | $3K | |
| G0136 | Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months | <1% | 236 | $3K |
| 81002 | <1% | 1,456 | $3K | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 730 | $3K |
| 83735 | <1% | 709 | $3K | |
| 93325 | <1% | 167 | $3K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 623 | $3K |
| 88108 | <1% | 403 | $3K | |
| 94621 | <1% | 27 | $3K | |
| 87350 | <1% | 459 | $3K | |
| 0074A | <1% | 68 | $3K | |
| 94729 | <1% | 61 | $3K | |
| 74170 | <1% | 12 | $3K | |
| 94727 | <1% | 79 | $2K | |
| 76775 | <1% | 52 | $2K | |
| 82274 | <1% | 489 | $2K | |
| 81005 | <1% | 1,750 | $2K | |
| 3080F | <1% | 3,090 | $2K | |
| 99195 | <1% | 19 | $2K | |
| 82977 | <1% | 441 | $2K | |
| 99426 | <1% | 40 | $2K | |
| 73030 | <1% | 61 | $2K | |
| 93227 | <1% | 152 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $2K |
| 90732 | <1% | 16 | $2K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 209 | $2K |
| 86592 | <1% | 697 | $2K | |
| 94060 | <1% | 72 | $2K | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 277 | $2K |
| 99427 | <1% | 24 | $2K | |
| 82962 | <1% | 1,065 | $2K | |
| 91319 | <1% | 46 | $2K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 222 | $2K |
| 91200 | <1% | 52 | $1K | |
| 83625 | <1% | 170 | $1K | |
| 1159F | <1% | 17,440 | $1K | |
| 90473 | <1% | 131 | $1K | |
| 76882 | <1% | 33 | $1K | |
| 83615 | <1% | 321 | $1K | |
| 82248 | <1% | 551 | $1K | |
| 85651 | <1% | 450 | $1K | |
| 84460 | <1% | 519 | $1K | |
| 92020 | <1% | 49 | $1K | |
| 1160F | <1% | 15,304 | $1K | |
| 82550 | <1% | 252 | $1K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 141 | $1K |
| 92504 | <1% | 44 | $1K | |
| 90662 | <1% | 77 | $974.76 | |
| 94760 | <1% | 2,992 | $969.21 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 493 | $809.19 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 497 | $799.97 |
| 87428 | <1% | 16 | $780.22 | |
| 10006 | <1% | 14 | $775.92 | |
| 3044F | <1% | 3,933 | $764.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,255 | $732.09 |
| 94664 | <1% | 74 | $683.88 | |
| 99223 | Prolong inpt eval add15 m | <1% | 13 | $661.77 |
| 92227 | <1% | 162 | $658.44 | |
| 90734 | <1% | 293 | $654.04 | |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | <1% | 58,645 | $627.25 |
| 90672 | <1% | 1,058 | $610.26 | |
| 83014 | <1% | 105 | $589.70 | |
| 86705 | <1% | 121 | $569.88 | |
| 90679 | <1% | 17 | $564.41 | |
| 84075 | <1% | 517 | $525.03 | |
| 86704 | <1% | 100 | $506.23 | |
| 73130 | <1% | 12 | $506.01 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 48 | $500.68 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 19 | $499.86 |
| 82247 | <1% | 653 | $498.17 | |
| 93922 | <1% | 16 | $493.89 | |
| 84450 | <1% | 517 | $487.96 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 481 | $474.42 |
| 90744 | <1% | 701 | $463.50 | |
| 92134 | <1% | 13 | $437.22 | |
| G0008 | Administration of influenza virus vaccine | <1% | 202 | $424.13 |
| G9275 | Documentation that patient is a current non-tobacco user | <1% | 49,055 | $408.35 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | <1% | 12,222 | $404.30 |
| 83550 | <1% | 422 | $398.36 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | <1% | 130,269 | $394.55 |
| 82040 | <1% | 355 | $371.76 | |
| 2023F | <1% | 343 | $362.25 | |
| 2000F | <1% | 137,462 | $359.20 | |
| 94375 | <1% | 14 | $353.44 | |
| 99429 | <1% | 13 | $325.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 314 | $314.08 |
| 84155 | <1% | 516 | $309.69 | |
| M1207 | Patient is screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety | <1% | 3,201 | $308.85 |
| 88738 | <1% | 128 | $307.74 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 522 | $300.26 |
| S0028 | Injection, famotidine, 20 mg | <1% | 549 | $268.21 |
| 87807 | <1% | 53 | $255.34 | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | <1% | 53,605 | $219.35 |
| 82270 | <1% | 181 | $200.41 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $198.30 |
| 90707 | <1% | 65 | $173.59 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 555 | $170.24 |
| 36406 | <1% | 20 | $136.36 | |
| 99050 | <1% | 39 | $133.06 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 306 | $128.89 |
| 3008F | <1% | 168,732 | $124.39 | |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | <1% | 4,298 | $112.55 |
| 90621 | <1% | 90 | $110.06 | |
| 92591 | <1% | 14 | $101.81 | |
| G8476 | Most recent blood pressure has a systolic measurement of < 140 mmhg and a diastolic measurement of < 90 mmhg | <1% | 14,180 | $86.75 |
| 0513F | <1% | 53 | $80.00 | |
| 82565 | <1% | 2,607 | $76.33 | |
| G9664 | Patients who are currently statin therapy users or received an order (prescription) for statin therapy | <1% | 6,794 | $63.49 |
| 2022F | <1% | 33 | $60.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 14 | $59.66 |
| 4008F | <1% | 256 | $59.20 | |
| 3022F | <1% | 255 | $58.11 | |
| 36416 | <1% | 775 | $57.70 | |
| 84436 | <1% | 1,160 | $55.79 | |
| G9920 | Screening performed and negative | <1% | 5,820 | $50.99 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 17,810 | $50.45 |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 24 | $49.13 |
| 76942 | <1% | 32 | $45.36 | |
| M1208 | Patient is not screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety | <1% | 181 | $45.15 |
| 99408 | <1% | 1,546 | $40.05 | |
| 3051F | <1% | 77 | $40.00 | |
| 4013F | <1% | 3,818 | $38.69 | |
| 90660 | <1% | 384 | $34.74 | |
| 96161 | <1% | 12 | $31.51 | |
| 81000 | <1% | 23 | $26.03 | |
| 3017F | <1% | 3,576 | $25.24 | |
| 1000F | <1% | 37,410 | $21.98 | |
| 1036F | <1% | 33,100 | $15.98 | |
| 3049F | <1% | 1,808 | $15.00 | |
| G8477 | Most recent blood pressure has a systolic measurement of >= 140 mmhg and/or a diastolic measurement of >= 90 mmhg | <1% | 910 | $14.10 |
| G8482 | Influenza immunization administered or previously received | <1% | 3,017 | $11.05 |
| G9621 | Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling | <1% | 1,169 | $10.25 |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | <1% | 26 | $9.69 |
| 3061F | <1% | 542 | $9.00 | |
| 4010F | <1% | 743 | $8.94 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14 | $8.21 |
| G9276 | Documentation that patient is a current tobacco user | <1% | 1,578 | $7.05 |
| 4145F | <1% | 280 | $5.68 | |
| 4086F | <1% | 146 | $5.67 | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 126 | $5.57 |
| 3016F | <1% | 36,355 | $5.33 | |
| 1125F | <1% | 84 | $5.00 | |
| 1126F | <1% | 144 | $5.00 | |
| 3725F | <1% | 33,107 | $4.55 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 3,832 | $3.00 |
| 3011F | <1% | 1,885 | $2.94 | |
| G8473 | Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed | <1% | 765 | $2.10 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 104 | $2.00 |
| G8418 | Bmi is documented below normal parameters and a follow-up plan is documented | <1% | 298 | $2.00 |
| 2010F | <1% | 617 | $1.24 | |
| 3210F | <1% | 111 | $1.00 | |
| 90670 | <1% | 183 | $0.47 | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 1,635 | $0.42 |
| 90671 | <1% | 186 | $0.25 | |
| 90698 | <1% | 153 | $0.25 | |
| 90680 | <1% | 191 | $0.25 | |
| 91313 | <1% | 35 | $0.11 | |
| 90716 | <1% | 55 | $0.08 | |
| 90697 | <1% | 28 | $0.06 | |
| 91312 | <1% | 15 | $0.05 | |
| 3050F | 0% | 1,777 | $0.00 | |
| 3288F | 0% | 3,752 | $0.00 | |
| G8598 | Aspirin or another antiplatelet therapy used | 0% | 62 | $0.00 |
| 4004F | 0% | 629 | $0.00 | |
| 90633 | 0% | 123 | $0.00 | |
| 99080 | 0% | 141 | $0.00 | |
| 97803 | 0% | 544 | $0.00 | |
| 99071 | 0% | 236 | $0.00 | |
| 3015F | 0% | 494 | $0.00 | |
| 1158F | 0% | 336 | $0.00 | |
| 0556F | 0% | 255 | $0.00 | |
| 90685 | 0% | 33 | $0.00 | |
| G8421 | Bmi not documented and no reason is given | 0% | 12 | $0.00 |
| 99499 | 0% | 49 | $0.00 | |
| 1032F | 0% | 176 | $0.00 | |
| 0521F | 0% | 26 | $0.00 | |
| S9449 | Weight management classes, non-physician provider, per session | 0% | 177 | $0.00 |
| 90700 | 0% | 14 | $0.00 | |
| 1124F | 0% | 79 | $0.00 | |
| 90648 | 0% | 60 | $0.00 | |
| 0518F | 0% | 15 | $0.00 | |
| G9507 | Documentation that the patient is on a statin medication or has documentation of a valid contraindication or exception to statin medications; contraindications/exceptions that can be defined by diagnosis codes include pregnancy during the measurement period, active liver disease, rhabdomyolysis, end stage renal disease on dialysis and heart failure; provider documented contraindications/exceptions include breastfeeding during the measurement period, woman of child-bearing age not actively taking birth control, allergy to statin, drug interaction (hiv protease inhibitors, nefazodone, cyclosporine, gemfibrozil, and danazol) and intolerance (with supporting documentation of trying a statin at least once within the last 5 years or diagnosis codes for myostitis or toxic myopathy related to drugs) | 0% | 28 | $0.00 |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 18 | $0.00 |
| 3511F | 0% | 18 | $0.00 | |
| 1101F | 0% | 3,719 | $0.00 | |
| 4037F | 0% | 16,297 | $0.00 | |
| 1157F | 0% | 121 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 234 | $0.00 |
| 99000 | 0% | 5,962 | $0.00 | |
| 3014F | 0% | 705 | $0.00 | |
| 3048F | 0% | 1,731 | $0.00 | |
| 4000F | 0% | 182 | $0.00 | |
| 1034F | 0% | 615 | $0.00 | |
| 2001F | 0% | 611 | $0.00 | |
| 4293F | 0% | 597 | $0.00 | |
| 3351F | 0% | 99 | $0.00 | |
| 1220F | 0% | 216 | $0.00 | |
| 1170F | 0% | 120 | $0.00 | |
| G8815 | Documented reason in the medical records for why the statin therapy was not prescribed (i.e., lower extremity bypass was for a patient with non-artherosclerotic disease) | 0% | 70 | $0.00 |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 111 | $0.00 |
| G8708 | Patient not prescribed antibiotic | 0% | 13 | $0.00 |
| S0257 | Counseling and discussion regarding advance directives or end of life care planning and decisions, with patient and/or surrogate (list separately in addition to code for appropriate evaluation and management service) | 0% | 282 | $0.00 |
| 3352F | 0% | 226 | $0.00 | |
| 3072F | 0% | 35 | $0.00 | |
| 1030F | 0% | 114 | $0.00 | |
| 90677 | 0% | 13 | $0.00 | |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 45 | $0.00 |
| 90381 | 0% | 26 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 54 | $0.00 |
| 1123F | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZHANG, JIAN WEI (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Metro True Care Medical, P.C. | New York, NY | $1.32M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.